Canexis Pharma Approved By Swissmedic: Can Produce 1000kg Per Day

Canexis Pharma approuvé par Swissmedic : peut produire 1000 kg par jour

mer, 24 Avr 2024

Canexis Pharma AG obtient une licence cruciale de Swissmedic, ce qui ouvre la voie à une production pharmaceutique avancée de cannabis en Suisse.

Canexis Pharma AG, a pioneering Swiss firm in pharmaceutical cannabis, announced today dans un communiqué de presse it has received crucial licenses from Swissmedic. This approval allows Canexis to commence production of high-quality CBD and THC-based pharmaceuticals for distribution in both Swiss and global markets.

Following an intense four-year development phase, production has begun at Canexis’ custom-designed facility in Schlattingen, Thurgau.

The plant, constructed to align with GMP standards, spans over 2,000 square meters, featuring state-of-the-art cleanrooms equipped with cutting-edge technology.

Inspection by Swissmedic has confirmed full compliance, paving the way for Canexis’ market entry later this year.

In just four years, we’ve built a pharmaceutical company from the ground up…We’re excited to transition from construction to contribution… and developing the pharmaceutical cannabis sector.
Sebastian Zeller, CEO of Canexis

The facility’s design and processes are optimised for cannabis extraction and processing, leveraging advanced European technology and knowledge-sharing with leading U.S. cannabis firms.

With the capacity to process up to 1,000 kg of cannabis, resulting in 100 kg of pure high-purity product daily, Canexis is well-positioned to supply between one to four million patients per day with pharmaceutical-grade cannabis products.

These products promise to enrich the medical cannabis market, currently dominated by bespoke prescription medicines, with a variety of standardised, high-purity pharmaceuticals.

Articles connexes

Sunflower Oil Prices in Switzerland Remain High

14 mai 2024

Despite global declines in sunflower oil prices, Swiss consumers still pay significantly more, raising concerns about...

SMI & Dow Jones On The Rise

17 mai 2024

Swiss stocks are up as the Dow Jones Industrial Average surpasses 40,000 points, driven by renewed interest rate hopes....

Swiss Insurance Helvetia Restructuring

16 mai 2024

Helvetia Insurance adapts its executive management and structure to boost international operations and innovation, with...

Foreign Minister Cassis Meets With The European Council

14 mai 2024

At the Council of Europe's meeting in Strasbourg, discussions will center on Ukraine support and AI regulation, marking...

UBS CEO: Bank Will Grow By 40% After CS Integration

16 mai 2024

UBS CEO Sergio Ermotti discusses the future size of UBS and regulatory changes at a Zurich event, emphasising the...

Swiss Universities Use Police To Disperse Student Protests

15 mai 2024

Police clear Unitobler building in Bern as occupiers comply without resistance. Universities are not negotiating. ...

Commerzbank Quarterly Earnings Surge

15 mai 2024

Commerzbank announces a pre-tax profit of nearly €1.1 billion for Q1, marking its best quarterly performance in over...

Rester en contact

À noter

Holcim Financial Performance Analysis: Q1 Insights

À noter

25 avril 2024

Analyse des performances financières de Holcim : Perspectives pour le premier trimestre

À noter

19 avril 2024

Canexis Pharma approuvé par Swissmedic : peut produire 1000 kg par jour

Canexis Pharma approuvé par Swissmedic : peut produire 1000 kg par jour

Articles connexes

Rester en contact

À noter

Analyse des performances financières de Holcim : Perspectives pour le premier trimestre

2 skieurs néerlandais échappent à la mort dans le canton de Vaud

Liens rapides